首页> 美国卫生研究院文献>AAPS PharmSciTech >Development and Characterization of Mixed Niosomes for Oral Delivery Using Candesartan Cilexetil as a Model Poorly Water-Soluble Drug
【2h】

Development and Characterization of Mixed Niosomes for Oral Delivery Using Candesartan Cilexetil as a Model Poorly Water-Soluble Drug

机译:使用坎地沙坦Cilexetil作为水难溶性药物的模型研究了用于口服给药的混合脂质体的研制与表征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this study was to prepare candesartan cilexetil-loaded niosomes and mixed niosomes to enhance the aqueous solubility of the drug, thus improving its oral bioavailability. The formulations were prepared using various types and combinations of surfactants, copolymers, and charge-inducing agents. The candesartan cilexetil entrapment efficiency, particle size, and zeta potential of these niosomes varied within the range of 99.06 ± 1.74 to 36.26 ± 2.78, 157.3 ± 3.3 to 658.3 ± 12.7 nm, and −14.7 ± 2.8 to −44.5 ± 1.5 mV, respectively. The in vitro drug release from niosomes was improved after niosomal entrapment compared to pure candesartan cilexetil. The sedimentation behavior study and formulation stability tests against bile salt revealed that mixed niosomes prepared by combining Span 60 and Pluronic P85 demonstrated better stability. The differential scanning calorimetry analysis showed the conversion of crystal structure of candesartan cilexetil to the soluble amorphous form after niosomal encapsulation which induced the drug release. Consequently, oral drug delivery by Span 60/Pluronic P85-mixed niosomes seems feasible due to enhanced drug release and stability.
机译:这项研究的目的是制备坎地沙坦西拉替尼负载的脂质体和混合的脂质体,以增强药物的水溶性,从而改善其口服生物利用度。使用表面活性剂,共聚物和电荷诱导剂的各种类型和组合制备制剂。这些脂质体的坎地沙坦酯的包封效率,粒径和ζ电势分别在99.06±±1.74至36.26±±2.78、157.3±±3.3至658.3±±12.7 nm和-14.7±±2.8至-44.5±±1.5 mV的范围内变化。 。与纯坎地沙坦西艾替舒相比,从尼奥体中捕获体外药物的释放有所改善。针对胆汁盐的沉降行为研究和制剂稳定性测试表明,由Span 60和Pluronic P85组合制备的混合脂质体具有更好的稳定性。差示扫描量热法分析表明,在包裹了蚕豆素后,坎地沙坦西酯的晶体结构转变为可溶的无定形形式,从而诱导了药物的释放。因此,由于增强的药物释放和稳定性,通过Span 60 / Pluronic P85混合脂质体口服给药似乎是可行的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号